$ACRS

Aclaris Therapeutics, Inc.

CIK:0001557746|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues:
Total revenue	$ 1,629	$ 1,777	$ 3,625	$ 3,232
Costs and expenses:
Cost of revenue	218	515	613	1,021
Research and development	18,066	11,449	33,723	23,033
General and administrative	6,048	5,386	12,791	11,525
Licensing	1,235	1,335	2,628	2,345
Revaluation of contingent consideration	300	1,500	300	1,800
Total costs and expenses	25,867	20,185	50,055	39,724
Loss from operations	(24,238)	(18,408)	(46,430)	(36,492)
Other income:
Interest income	1,761	2,018	3,275	4,184
Non-cash royalty income	972	961	1,826	1,794
Total other income	2,733	2,979	5,101	5,978
Net loss	$ (21,505)	$ (15,429)	$ (41,329)	$ (30,514)
Net loss per share, basic	$ (0.15)	$ (0.13)	$ (0.3)	$ (0.25)
Net loss per share, diluted	$ (0.15)	$ (0.13)	$ (0.3)	$ (0.25)
Weighted average common shares outstanding, basic	142,736,848	122,580,967	135,811,921	122,486,162
Weighted average common shares outstanding, diluted	142,736,848	122,580,967	135,811,921	122,486,162
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities, net of tax of $0	$ (326)	$ 48	$ (914)	$ 385
Total other comprehensive (loss) income	(326)	48	(914)	385
Comprehensive loss	(21,831)	(15,381)	(42,243)	(30,129)
Contract research
Revenues:
Total revenue	356	442	893	887
Licensing
Revenues:
Total revenue	$ 1,273	$ 1,335	$ 2,732	$ 2,345

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (41,329)	$ (30,514)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	209	242
Stock-based compensation expense	5,870	6,598
Revaluation of contingent consideration	300	1,800
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets	(477)	7,155
Accounts payable	2,355	4,107
Accrued expenses and other liabilities	(3,098)	(10,643)
Deferred income	(1,826)	(1,795)
Net cash used in operating activities	(37,996)	(23,050)
Cash flows from investing activities:
Purchases of property and equipment	(71)	(64)
Purchases of marketable securities	(60,598)	(29,926)
Proceeds from sales and maturities of marketable securities	40,000	54,989
Payments of deferred transaction consideration for in-licensed assets		(833)
Net cash (used in) provided by investing activities	(20,669)	24,166
Cash flows from financing activities:
Proceeds from issuance of common stock under the at-the-market sales agreement, net of issuance costs	57,880
Payments of employee withholding taxes related to restricted stock unit award vesting	(273)	(284)
Proceeds from exercise of employee stock options and the issuance of stock	265
Net cash provided by (used in) financing activities	57,872	(284)
Net (decrease) increase in cash and cash equivalents	(793)	832
Cash and cash equivalents at beginning of period	19,960	24,570
Cash and cash equivalents at end of period	19,167	$ 25,402
Supplemental disclosure of non-cash investing activities:
Additions to property and equipment included in accounts payable	$ 3

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 19,167	$ 19,960
Short-term marketable securities	72,389	70,791
Accounts receivable, prepaid expenses and other current assets	6,209	5,565
Total current assets	97,765	96,316
Marketable securities	79,065	60,612
Property and equipment, net	664	761
Other assets	2,199	2,771
Total assets	179,693	160,460
Current liabilities:
Accounts payable	15,516	13,158
Accrued expenses	5,959	8,791
Deferred income	3,976	3,943
Other current liabilities	2,790	2,753
Total current liabilities	28,241	28,645
Other liabilities	1,262	1,565
Deferred income, net of current portion	14,309	16,168
Contingent consideration	11,300	11,000
Total liabilities	55,112	57,378
Stockholders' Equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.00001 par value; 400,000,000 shares authorized at June 30, 2026 and December 31, 2025; 139,824,273 and 120,499,433 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	1	1
Additional paidin capital	1,133,997	1,070,255
Accumulated other comprehensive (loss) income	(304)	610
Accumulated deficit	(1,009,113)	(967,784)
Total stockholders' equity	124,581	103,082
Total liabilities and stockholders' equity	$ 179,693	$ 160,460